de la Fuente-Nunez is a presidential associate professor at the University of Pennsylvania. Skinner is CEO of the AMR Action Fund. Of all the areas of drug development that artificial intelligence has ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is also the author of the morning Pharmalittle newsletter ...

Antibiotics are a crucial tool in the fight against bacterial infections. But the World Health Organization has long warned that we are facing an antibiotic crisis. Bacteria can easily adapt, evolve, ...

Purdue researchers developed a mass spectrometry platform that accelerates cancer drug discovery by integrating synthesis, ...

Scientists from the University of Tübingen and Monash University studied glycopeptide antibiotics, a key resource in countering drug-resistant pathogens, to uncover their evolutionary origins to gain ...

Antimicrobial resistance (AMR) is an inevitable evolutionary process — resistance will occur, and it will spread globally. We are in a race to maintain a portfolio of effective antibiotics, and we are ...

While biopharma’s overarching mission is to develop innovative medicines to improve patient outcomes, for these six people, ...

Companies see a commercial opportunity in creating new ways to administer drugs to patients – in space.